人源化CD19靶向嵌合抗原受体T(CAR-T)细胞在复发/难治性急性淋巴细胞白血病患者中具有强效抗白血病活性
研究采用源自鼠源FMC63抗体的人源化scFv构建CD19 CAR-T细胞(hCART19s),治疗18例复发/难治性急性淋巴细胞白血病患者,其中14例既往未接受CAR-T治疗者中13例(92.9%)在第30天达完全缓解或伴血细胞计数未完全恢复的完全缓解,3例二次鼠源CAR-T输注失败者中1例经hCART19s达完全缓解。
要点
- 14例既往未接受CAR-T治疗者中13例(92.9%)第30天达完全缓解或伴计数未完全恢复的完全缓解。
- 3例二次鼠源CAR-T输注失败者中1例经hCART19s输注后达完全缓解。
- 13例发生1-2级细胞因子释放综合征,4例发生3-5级,1例出现可逆性神经毒性。
核心结论
- hCART19s可在复发/难治性B细胞急性淋巴细胞白血病患者中诱导缓解,尤其在接受鼠源CAR-T再输注的患者中。
研究设计与样本
- 研究纳入18例复发/难治性急性淋巴细胞白血病患者,其中部分既往接受过鼠源CD19 CAR-T治疗。
- 患者经环磷酰胺和氟达拉滨清淋化疗后,接受单次剂量1×10^6/kg自体hCART19s输注。
主要发现
- 14例既往未接受CAR-T治疗患者中13例(92.9%)在第30天达完全缓解或伴血细胞计数未完全恢复的完全缓解。
- 3例二次鼠源CAR-T输注失败患者中1例经hCART19s输注后达完全缓解。
- 第180天总生存率和无白血病生存率分别为65.8%和71.4%。
- 累积复发发生率为22.6%,非复发死亡率为7.1%。
- 治疗期间13例发生1-2级细胞因子释放综合征,4例发生3-5级细胞因子释放综合征,1例出现可逆性神经毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T (CAR-T) cell therapy has shown promising results for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The immune response induced by murine single-chain variable fragment (scFv) of the CAR may limit CAR-T cell persistence and thus increases the risk of leukemia relapse. In this study, we developed a novel humanized scFv from the murine FMC63 antibody. A total of 18 R/R ALL patients with or without prior murine CD19 CAR-T therapy were treated with humanized CD19-targeted CAR-T cells (hCART19s). After lymphodepletion chemotherapy with cyclophosphamide and fludarabine, the patients received a single dose (1 × 106 /kg) of autologous hCART19s infusion. Among the 14 patients without previous CAR-T therapy, 13 (92.9%) achieved complete remission (CR) or CR with incomplete count recovery (CRi) on day 30, whereas 1 of the 3 patients who failed a second murine CAR-T infusion achieved CR after hCART19s infusion. At day 180, the overall and leukemia-free survival rates were 65.8% and 71.4%, respectively. The cumulative incidence of relapse was 22.6%, and the nonrelapse mortality rate was 7.1%. During treatment, 13 patients developed grade 1-2 cytokine release syndrome (CRS), 4 patients developed grade 3-5 CRS, and 1 patient experienced reversible neurotoxicity. These results indicated that hCART19s could induce remission in patients with R/R B-ALL, especially in patients who received a reinfusion of murine CAR-T.
引用
- Cao J, Wang G, Cheng H, et al. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2018. PMID: 29633386. doi:10.1002/ajh.25108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。